Trends and incidence of stomach cancer in middle-aged and elderly populations: a global burden of disease analysis
Journal of Gastrointestinal Oncology · 2025-10 · 16 (5) · 1890-1901
DOI: 10.21037/jgo-2025-151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastrointestinal Oncology, 2025-10. Verfasst von Yubao Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Affiliated Yangzhou Women and Children's Hospital, Yangzhou University School of Medicine, Yangzhou, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Stomach cancer remains a leading cause of cancer deaths in middle-aged and elderly populations. This study aimed to examine global trends in incidence among individuals aged 50-74 years and to explore disparities by age, sex, and region using Global Burden of Disease (GBD) data.
Methods
Data on stomach cancer incidence were extracted from the GBD 2021 database. We analyzed incidence rates for individuals aged 50-74 years, stratified by age, sex, and geographic region. Trends from 1990 to 2021 were evaluated using the Estimated Annual Percentage Change (EAPC) based on log-linear regression models. Pearson correlation was used to examine associations between incidence trends and the Socio-Demographic Index (SDI). Data standardization was based on the GBD world standard population.
Results
From 1990 to 2021, the number of stomach cancer cases among individuals aged 50-74 years increased by 17.32%, while the incidence rates declined from 80.67 to 44.18 per 100,000 (EAPC: -2.15). Males consistently exhibited higher incidence rates than females. The decline was less pronounced in older age groups, particularly those aged 65-74 years, where the number of cases continued to rise, reflecting population aging and cumulative risk exposure. High-SDI regions experienced the largest reductions (e.g., East Asia: EAPC -2.02), whereas progress was limited in low-SDI areas such as Southern and Eastern Sub-Saharan Africa. A strong negative correlation between SDI and incidence trends (ρ=-0.491) underscored the influence of socioeconomic development on disease reduction.
Conclusions
This study reveals marked regional and demographic disparities in stomach cancer trends among aging populations. Socioeconomic development plays a central role in reducing incidence. To reduce global health inequities, efforts should prioritize equitable access to screening and treatment, culturally tailored prevention programs, and investment in healthcare infrastructure in low-SDI regions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Affiliated Yangzhou Women and Children's Hospital, Yangzhou University School of Medicine, Yangzhou, China.
- Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
- Xi'an Medical University, Xi'an, China.
- Department of Oncology, The Affiliated Children's Hospital of Jiangnan University, Wuxi, China.
ORCID-Profile: Dong Hua
Zitieren
APA
Tang, Y., Wang, D., Xu, Z., Wang, H., Tian, H., Wang, W., & Hua, D. (2025). Trends and incidence of stomach cancer in middle-aged and elderly populations: a global burden of disease analysis. Journal of Gastrointestinal Oncology, 16(5), 1890-1901. https://doi.org/10.21037/jgo-2025-151
Vancouver
Tang Y, Wang D, Xu Z, Wang H, Tian H, Wang W, et al. Trends and incidence of stomach cancer in middle-aged and elderly populations: a global burden of disease analysis. Journal of Gastrointestinal Oncology. 2025;16(5):1890-1901. doi:10.21037/jgo-2025-151
BibTeX
@article{Tang2025,
author = {Tang, Yubao and Wang, Danyang and Xu, Zhicheng and Wang, Hanyu and Tian, Haixia and Wang, Weijing and Hua, Dong},
title = {Trends and incidence of stomach cancer in middle-aged and elderly populations: a global burden of disease analysis},
journal = {Journal of Gastrointestinal Oncology},
year = {2025},
volume = {16},
number = {5},
pages = {1890--1901},
doi = {10.21037/jgo-2025-151}
}
EUVIMED